What is the share price of Glenmark Pharmaceuticals Ltd (GLENMARK) today?
The share price of GLENMARK as on 16th July 2025 is ₹2224.10. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Glenmark Pharmaceuticals Ltd (GLENMARK) share?
The past returns of Glenmark Pharmaceuticals Ltd (GLENMARK) share are- Past 1 week: 19.50%
- Past 1 month: 32.56%
- Past 3 months: 61.67%
- Past 6 months: 50.69%
- Past 1 year: 58.09%
- Past 3 years: 485.05%
- Past 5 years: 435.38%
What are the peers or stocks similar to Glenmark Pharmaceuticals Ltd (GLENMARK)?
The peers or stocks similar to Glenmark Pharmaceuticals Ltd (GLENMARK) include:What is the dividend yield % of Glenmark Pharmaceuticals Ltd (GLENMARK) share?
The current dividend yield of Glenmark Pharmaceuticals Ltd (GLENMARK) is 0.11.What is the market cap of Glenmark Pharmaceuticals Ltd (GLENMARK) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Glenmark Pharmaceuticals Ltd (GLENMARK) is ₹62820.72 Cr as of 16th July 2025.What is the 52 week high and low of Glenmark Pharmaceuticals Ltd (GLENMARK) share?
The 52-week high of Glenmark Pharmaceuticals Ltd (GLENMARK) is ₹2284.80 and the 52-week low is ₹1275.50.What is the PE and PB ratio of Glenmark Pharmaceuticals Ltd (GLENMARK) stock?
The P/E (price-to-earnings) ratio of Glenmark Pharmaceuticals Ltd (GLENMARK) is 60.00. The P/B (price-to-book) ratio is 8.01.Which sector does Glenmark Pharmaceuticals Ltd (GLENMARK) belong to?
Glenmark Pharmaceuticals Ltd (GLENMARK) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Glenmark Pharmaceuticals Ltd (GLENMARK) shares?
You can directly buy Glenmark Pharmaceuticals Ltd (GLENMARK) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Glenmark Pharmaceuticals Ltd
GLENMARK Share Price
GLENMARK Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
BadThe stock is overpriced and in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
GLENMARK Performance & Key Metrics
GLENMARK Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
59.99 | 8.01 | 0.11% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
37.80 | 6.51 | 0.80% |
from 11 analysts
Price Upside
Earnings Growth
Rev. Growth
GLENMARK Company Profile
Glenmark Pharmaceuticals Limited is a global pharmaceutical company engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).
GLENMARK Forecast
GLENMARK Forecasts
Price
Revenue
Earnings
GLENMARK Share Price Forecast
GLENMARK Share Price Forecast
All values in ₹
All values in ₹
GLENMARK Company Revenue Forecast
GLENMARK Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
GLENMARK Stock EPS (Earnings Per Share) Forecast
GLENMARK Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
GLENMARK
GLENMARK
Income
Balance Sheet
Cash Flow
GLENMARK Income Statement
GLENMARK Income Statement
Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 9,116.78 | 9,165.82 | 10,240.79 | 10,833.45 | 11,038.69 | 12,471.57 | 12,339.10 | 13,050.42 | 13,435.46 | 13,435.46 | ||||||||||
Raw Materials | 3,073.93 | 2,904.86 | 3,421.01 | 3,570.56 | 3,809.43 | 4,396.42 | 4,498.19 | 4,608.99 | 11,343.18 | 11,343.17 | ||||||||||
Power & Fuel Cost | 127.02 | 137.48 | 165.26 | 173.69 | 164.67 | 200.64 | 111.75 | 124.00 | ||||||||||||
Employee Cost | 1,640.81 | 1,871.84 | 2,056.07 | 2,254.78 | 2,343.71 | 2,447.42 | 2,600.78 | 2,868.14 | ||||||||||||
Selling & Administrative Expenses | 1,589.86 | 1,523.27 | 1,750.21 | 1,667.02 | 1,453.55 | 1,543.27 | 1,752.30 | 1,708.60 | ||||||||||||
Operating & Other expenses | 692.04 | 1,021.60 | 887.12 | 1,276.84 | 1,088.19 | 1,657.76 | 1,751.06 | 2,208.99 | ||||||||||||
EBITDA | 1,993.12 | 1,706.77 | 1,961.12 | 1,890.56 | 2,179.14 | 2,226.06 | 1,625.02 | 1,531.70 | 2,092.28 | 2,092.29 | ||||||||||
Depreciation/Amortization | 264.37 | 301.88 | 325.91 | 417.17 | 443.55 | 486.72 | 569.17 | 581.91 | 486.01 | 486.02 | ||||||||||
PBIT | 1,728.75 | 1,404.89 | 1,635.21 | 1,473.39 | 1,735.59 | 1,739.34 | 1,055.85 | 949.79 | 1,606.27 | 1,606.27 | ||||||||||
Interest & Other Items | 237.32 | 285.57 | 334.59 | 377.32 | 353.11 | 298.10 | 349.04 | 515.97 | 207.07 | 207.06 | ||||||||||
PBT | 1,491.43 | 1,119.32 | 1,300.62 | 1,096.07 | 1,382.48 | 1,441.24 | 706.81 | 433.82 | 1,399.20 | 1,399.21 | ||||||||||
Taxes & Other Items | 382.67 | 315.46 | 375.63 | 320.11 | 412.44 | 499.54 | 409.56 | 1,935.49 | 352.12 | 352.10 | ||||||||||
Net Income | 1,108.76 | 803.86 | 924.99 | 775.96 | 970.04 | 941.70 | 297.25 | -1,501.67 | 1,047.08 | 1,047.11 | ||||||||||
EPS | 39.29 | 28.49 | 32.78 | 27.50 | 34.38 | 33.37 | 10.53 | -53.22 | 37.11 | 37.11 | ||||||||||
DPS | 2.00 | 2.00 | 2.00 | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 | ||||||||||
Payout ratio | 0.05 | 0.07 | 0.06 | 0.09 | 0.07 | 0.07 | 0.24 | — | 0.07 | 0.07 |
GLENMARK Company Updates
Investor Presentation
GLENMARK Stock Peers
GLENMARK Past Performance & Peer Comparison
GLENMARK Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Glenmark Pharmaceuticals Ltd | 60.00 | 8.01 | 0.11% |
Sun Pharmaceutical Industries Ltd | 37.93 | 5.72 | 0.93% |
Cipla Ltd | 22.84 | 3.85 | 1.07% |
Torrent Pharmaceuticals Ltd | 60.91 | 15.34 | 0.93% |
GLENMARK Stock Price Comparison
Compare GLENMARK with any stock or ETFGLENMARK Holdings
GLENMARK Shareholdings
GLENMARK Promoter Holdings Trend
GLENMARK Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
GLENMARK Institutional Holdings Trend
GLENMARK Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
GLENMARK Shareholding Pattern
GLENMARK Shareholding Pattern
GLENMARK Shareholding History
GLENMARK Shareholding History
Mutual Funds Invested in GLENMARK
Mutual Funds Invested in GLENMARK
No mutual funds holding trends are available
Top 5 Mutual Funds holding Glenmark Pharmaceuticals Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 2.9727% | Percentage of the fund’s portfolio invested in the stock 2.21% | Change in the portfolio weight of the stock over the last 3 months 0.35% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 7/81 (+2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.7732% | Percentage of the fund’s portfolio invested in the stock 1.18% | Change in the portfolio weight of the stock over the last 3 months -0.22% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 64/112 (-6) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.5857% | Percentage of the fund’s portfolio invested in the stock 1.38% | Change in the portfolio weight of the stock over the last 3 months -0.26% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 49/91 (0) |
Compare 3-month MF holding change on Screener
smallcases containing GLENMARK stock
smallcases containing GLENMARK stock
Looks like this stock is not in any smallcase yet.
GLENMARK Events
GLENMARK Events
GLENMARK Dividend Trend
GLENMARK has increased or maintained dividend levels over the last 5 years
Current dividend yield is 0.11%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.13 every year
Dividends
Corp. Actions
Announcements
Legal Orders
GLENMARK Dividend Trend
GLENMARK has increased or maintained dividend levels over the last 5 years
Current dividend yield is 0.11%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.13 every year
GLENMARK Upcoming Dividends
GLENMARK Upcoming Dividends
No upcoming dividends are available
GLENMARK Past Dividends
GLENMARK Past Dividends
Cash Dividend
Ex DateEx DateSep 13, 2024
Dividend/Share
₹2.50
Ex DateEx Date
Sep 13, 2024
Cash Dividend
Ex DateEx DateSep 18, 2023
Dividend/Share
₹2.50
Ex DateEx Date
Sep 18, 2023
Cash Dividend
Ex DateEx DateSep 12, 2022
Dividend/Share
₹2.50
Ex DateEx Date
Sep 12, 2022
Cash Dividend
Ex DateEx DateSep 8, 2021
Dividend/Share
₹2.50
Ex DateEx Date
Sep 8, 2021
Cash Dividend
Ex DateEx DateSep 17, 2020
Dividend/Share
₹2.50
Ex DateEx Date
Sep 17, 2020
GLENMARK Stock News & Opinions
GLENMARK Stock News & Opinions
Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 2214.7, up 1.54% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.4% on the day, quoting at 25050.1. The Sensex is at 82139.43, down 0.44%. Glenmark Pharmaceuticals Ltd has gained around 31.56% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 2% in last one month and is currently quoting at 22225.9, up 1.15% on the day. The volume in the stock stood at 27.13 lakh shares today, compared to the daily average of 18.89 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 2223, up 1.92% on the day. Glenmark Pharmaceuticals Ltd is up 57.28% in last one year as compared to a 1.88% jump in NIFTY and a 7.85% jump in the Nifty Pharma index.The PE of the stock is 35.29 based on TTM earnings ending March 25.Powered by Capital Market - Live
The USFDA inspection was conducted between 3 February and 14 February 2025. In an official filing, the company stated that it does not anticipate the warning letter will disrupt supply chains or affect revenues generated from the Indore facility. Glenmark emphasized its commitment to addressing the FDA's concerns promptly and working closely with the regulator to resolve the issues. The company further clarified that there were no observations related to data integrity during the inspection. Glenmark reaffirmed its dedication to maintaining the highest quality and compliance standards, including adherence to Current Good Manufacturing Practices (CGMP), across all its facilities. Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. On a consolidated basis, Glenmark Pharmaceuticals reported a net profit of Rs 4.65 crore in Q4 March 2025 as against a net loss of Rs 1,218.28 crore in Q4 March 2024. Net sales rose 6.77% year-on-year to Rs 3220.13 crore in Q4 March 2025. The scrip shed 0.56% to Rs 2,169.30 on the BSE. Powered by Capital Market - Live
Netweb Technologies India Ltd, Globus Spirits Ltd, VST Industries Ltd and Jaiprakash Power Ventures Ltd are among the other gainers in the BSE's 'A' group today, 11 July 2025.Glenmark Pharmaceuticals Ltd spiked 15.00% to Rs 2190.9 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 1.04 lakh shares were traded on the counter so far as against the average daily volumes of 21923 shares in the past one month. Netweb Technologies India Ltd surged 5.47% to Rs 1912.4. The stock was the second biggest gainer in 'A' group. On the BSE, 1.02 lakh shares were traded on the counter so far as against the average daily volumes of 21540 shares in the past one month. Globus Spirits Ltd soared 5.30% to Rs 1011.55. The stock was the third biggest gainer in 'A' group. On the BSE, 30438 shares were traded on the counter so far as against the average daily volumes of 5407 shares in the past one month. VST Industries Ltd gained 5.30% to Rs 295.85. The stock was the fourth biggest gainer in 'A' group. On the BSE, 57356 shares were traded on the counter so far as against the average daily volumes of 52831 shares in the past one month. Jaiprakash Power Ventures Ltd exploded 5.13% to Rs 24.2. The stock was the fifth biggest gainer in 'A' group. On the BSE, 316.68 lakh shares were traded on the counter so far as against the average daily volumes of 197.32 lakh shares in the past one month. Powered by Capital Market - Live
The announcement follows a major licensing agreement with U.S. biopharma giant AbbVie. Under the terms of the agreement, IGI will collaborate with AbbVie to develop, manufacture, and commercialize ISB 2001, a first-in-class trispecific T-cell engager designed to treat multiple myeloma. AbbVie will handle development and commercialization in North America, Europe, Japan, and Greater China. Glenmark Pharmaceuticals will take charge of manufacturing and marketing the therapy in Emerging Markets, including Asia (excluding key developed markets), Latin America, the Russia/CIS region, the Middle East, Africa, Australia, New Zealand, and South Korea. ISB 2001, currently in Phase 1 clinical development, targets BCMA and CD38 on myeloma cells and CD3 on T cells. Developed using IGI's proprietary BEAT protein platform, the asset is engineered to enhance efficacy even at low antigen expression levels while aiming to improve safety over traditional bispecific antibodies. Data presented at the 2025 ASCO Annual Meeting showed promising results: a 79% overall response rate and 30% complete/stringent complete response in a heavily pretreated patient population. The therapy has also received Orphan Drug Designation (July 2023) and Fast Track Designation (May 2025) from the U.S. FDA for relapsed/refractory multiple myeloma. With this landmark deal, Glenmark is poised to strengthen its footprint in the global oncology market while expanding patient access to next-gen immunotherapies across high-need regions. Our collaboration with AbbVie and Glenmark reflects IGI's mission to accelerate access to transformative multispecifics for patients worldwide, said Cyril Konto, M.D., President, Executive Director and CEO of IGI. AbbVie's reach in major markets combined with Glenmark's commercial strength in Emerging Markets, creates complementary access pathways for ISB 2001, a trispecific T-cell engager with promising potential in Multiple Myeloma. At Glenmark, we are committed to expanding access to innovative cancer treatments across Emerging Markets where unmet need and growth potential intersect, said Christoph Stoller, President ' Europe and Emerging Markets, Glenmark Pharmaceuticals. The addition of ISB 2001 is a natural evolution of our oncology strategy. With our deep commercial footprint, strong regulatory capabilities, and experience in launching breakthrough assets like BRUKINSA and TEVIMBRA in India, and rights to commercialize QiNHAYO (envafolimab), a PD-L1 checkpoint inhibitor, in Emerging Markets, we are well positioned to deliver impactful treatment option for patients with difficult-to-treat cancers through ISB 2001. Headquartered in New York, IGI is a global, fully integrated clinical-stage biotechnology company focused on developing innovative biologics in oncology. Glenmark Pharmaceuticals is a research‐led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. On a consolidated basis, Glenmark Pharmaceuticals reported a net profit of Rs 4.65 crore in Q4 March 2025 as against a net loss of Rs 1,218.28 crore in Q4 March 2024. Net sales rose 6.77% year-on-year to Rs 3220.13 crore in Q4 March 2025. Powered by Capital Market - Live
IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT' protein platform, for oncology and autoimmune diseases. 'Multispecifics including trispecific antibodies represent a new frontier in immuno-oncology with the potential to deliver deeper, more durable responses by engaging multiple targets simultaneously,' said Roopal Thakkar, M.D., Executive Vice-President, Research and Development and Chief Scientific Officer, AbbVie. 'This partnership with IGI reflects our unwavering commitment to advancing novel therapies for patients with multiple myeloma, a disease where significant unmet need remains despite recent progress.' 'ISB 2001 exemplifies the potential of our BEAT' protein platform to generate effective multispecifics that may overcome resistance and improve outcomes in hard-to-treat cancers,' said Cyril Konto, M.D., President and CEO of IGI. This agreement marks a defining milestone in IGI's scientific journey and reflects our team's deep commitment to delivering meaningful therapies for patients. Our partnership with AbbVie accelerates ISB 2001's path to patients and sharpens our focus on advancing the next generation of BEAT'-enabled assets in oncology.' Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China. Subject to regulatory clearance, IGI will receive an upfront payment of $700 million and is eligible to receive up to $1.225 billion in development, regulatory, and commercial milestone payments, along with tiered, double-digit royalties on net sales. Powered by Capital Market - Live
Glenmark Pharmaceuticals Ltd gained for a fifth straight session today. The stock is quoting at Rs 1812.1, up 1.6% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.18% on the day, quoting at 25360.65. The Sensex is at 83104.96, down 0.16%. Glenmark Pharmaceuticals Ltd has gained around 14.34% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 3.4% in last one month and is currently quoting at 22204.25, up 0.79% on the day. The volume in the stock stood at 3.99 lakh shares today, compared to the daily average of 10.37 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 1821.7, up 1.76% on the day. Glenmark Pharmaceuticals Ltd is up 35.42% in last one year as compared to a 4.26% jump in NIFTY and a 9.41% jump in the Nifty Pharma index.The PE of the stock is 28.84 based on TTM earnings ending March 25.Powered by Capital Market - Live
Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 1773.3, up 1.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.22% on the day, quoting at 25484.65. The Sensex is at 83437.68, down 0.31%. Glenmark Pharmaceuticals Ltd has gained around 17.13% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 3.58% in last one month and is currently quoting at 22041.25, up 0.35% on the day. The volume in the stock stood at 2.49 lakh shares today, compared to the daily average of 11.89 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 1779.6, up 0.78% on the day. Glenmark Pharmaceuticals Ltd is up 38.34% in last one year as compared to a 4.93% jump in NIFTY and a 11.06% jump in the Nifty Pharma index.The PE of the stock is 28.38 based on TTM earnings ending March 25.Powered by Capital Market - Live
Glenmark Pharmaceuticals (Glenmark) launched TEVIMBRA' (tislelizumab) in India following the approval by Central Drugs Standard Control Organization (CDSCO). TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines), a global oncology leader committed to delivering advanced treatments for cancer patients worldwide. It is indicated for the treatment of first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy and second-line treatment of locally advanced or metastatic NSCLC and esophageal squamous cell carcinoma (ESCC) as monotherapy. This launch marks Glenmark's first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio. NSCLC is the most common type of lung cancer, representing over 80% of all lung cancer cases. Similarly, ESCC is the most common histological subtype of esophageal cancer in India. TEVIMBRA caters to the needs of this significant patient population by offering a differentiated and proven treatment option for these cancers. TEVIMBRA is approved and marketed in multiple leading global markets including the United States, European Union, Australia and China. Designed to selectively bind to PD-1 receptors, TEVIMBRA restores T-cell function while minimizing off-target immune suppression and has demonstrated robust efficacy with a favorable safety profile across diverse solid tumor types in multiple pivotal Phase 3 studies and through a comprehensive global clinical development program.Powered by Capital Market - Live
The key domestic indices pared all gains and traded with minor losses in mid-morning trade, amid ongoing geopolitical tensions between Israel and Iran. Market direction remains sensitive to geopolitical developments. Investors will closely monitor crude oil prices, developments from the G7 summit and the outcome of the upcoming U.S. Federal Reserve meeting. The Nifty slipped below the 24,850 mark. Media shares witnessed selling pressure for the second consecutive trading session. At 11:25 IST, the barometer index, the S&P BSE Sensex declined 195.99 points or 0.24% to 81,390.04. The Nifty 50 index declined 46.05 points or 0.19% to 24,807.80. In the broader market, the S&P BSE Mid-Cap index fell 0.27% and the S&P BSE Small-Cap index shed 0.13%. The market breadth was negative. On the BSE, 1,634 shares rose and 2,046 shares fell. A total of 270 shares were unchanged. IPO Update: The initial public offer (IPO) of Arisinfra Solutions received bids for 10,08,216 shares as against 1,30,84,656 shares on offer, according to stock exchange data at 11:24 IST on Wednesday (18 June 2025). The issue was subscribed 0.08 times. The issue opened for bidding on Wednesday (18 June 2025) and it will close on Friday (20 June 2025). The price band of the IPO is fixed between Rs 210 and 222 per share. An investor can bid for a minimum of 67 equity shares and in multiples thereof. Buzzing Index: The Nifty Media index fell 0.83% to 1,709.05. The index declined 1.55% for the two consecutive trading sessions. Dish TV India (down 2.05%), Saregama India (down 1.69%), D B Corp (down 1.38%), Zee Entertainment Enterprises (down 1.31%), Sun TV Network (down 0.89%), Tips Music (down 0.67%), Hathway Cable & Datacom (down 0.47%) and Network 18 Media & Investments (down 0.32%) declined. Stocks in Spotlight: Glenmark Pharmaceuticals rose 0.26%. The company announced that its manufacturing facility in Monroe, North Carolina, USA, has received a Form 483 with five procedural observations from the United States Food and Drug Administration (USFDA). Polycab India shed 0.32%. The company said that it has executed a contract worth Rs 6,447.54 crore with Bharat Sanchar Nigam (BSNL) to act as the project implementation agency (PIA) for the BharatNet project in Karnataka, Goa, and Puducherry. Global Markets: Markets in Asia traded in a mixed fashion on Wednesday, as escalating tensions between Israel and Iran weigh on investor sentiment. Adding fuel to fire, U.S. President Donald Trump is mulling a military strike on Iran, while demanding the country's leader Ayatollah Ali Khamenei 'surrender,' media reports stated. Japan exports in May declined 1.7% year on year, which is lower than the decline of 3.8% that was widely anticipated by the markets. The data comes a day after the Bank of Japan highlighted in its monetary policy statement that the country's growth was likely to 'moderate' on the back of factors like trade, which would lead to a slowdown in overseas economies and a decline in domestic corporate profits. On the Wall Street, all three major averages ended the trading day lower. The Dow Jones Industrial Average lost 299.29 points, or 0.70%, to close at 42,215.80. The S&P 500 shed 0.84% to end at 5,982.72, while the Nasdaq Composite fell 0.91% and settled at 19,521.09. The key indices ended lower ahead of the US Federal Reserve's rate decision, which is due Wednesday afternoon. The U.S. central bank is widely expected to hold rates steady, but investors will be keeping a close eye on Fed Chair Jerome Powell's post-meeting comments. Traders are also watching for policymakers' forecast on rate policy, as the Federal Open Market Committee will be sharing members' 'dot plot' of rate expectations.Powered by Capital Market - Live
According to a regulatory filing by the company, the USFDA conducted a good manufacturing practices (GMP) inspection at the Monroe site from 9 June to 17 June 2025. Following the conclusion of the inspection, the USFDA has issued a Form 483 with five observations. Glenmark clarified that all the observations are procedural in nature and none pertain to data integrity. The company stated that it will work closely with the USFDA to address the observations and will submit its response within the stipulated timeline. Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. On a consolidated basis, Glenmark Pharmaceuticals reported net profit of Rs 4.65 crore in Q4 March 2025 as against net loss of Rs 1,218.28 crore in Q4 March 2024. Net sales rose 6.77% year-on-year to Rs 3220.13 crore in Q4 March 2025. The counter shed 0.30% to Rs 1,648.80 on the BSE. Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 4.4%, vs industry avg of 10.15%
Over the last 5 years, market share decreased from 4.31% to 3.22%
Over the last 5 years, net income has grown at a yearly rate of 6.18%, vs industry avg of 20.04%